Respiratory medicine · 2011
The influence of Flutter®VRP1 components on mucus transport of patients with bronchiectasis.
СтатьяРандомизированное исследованиеПоддержка исследования: вне правительства СШАНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Tambascio Joana, de Souza Léa Tatiana, Lisboa Roberta M, Passarelli Rita de Cássia V, de Souza Hugo Celso Dutra, Gastaldi Ada Clarice
Аннотация
BACKGROUND: The Flutter(®)VRP1 combines high frequency oscillation and positive expiratory pressure (PEP).
OBJECTIVE: To separately evaluate the effect of the Flutter(®)VRP1 components (high frequency oscillation and PEP) on mucus transportability in patients with bronchiectasis.
METHODS: Eighteen patients with bronchiectasis received sessions with the Flutter(®)VRP1 or PEP for 30 min daily in a randomized, crossover study. The treatment duration was four weeks with one of the therapies, one week of a "wash-out" period and followed by four more weeks with the other treatment. Weekly secretion samples were collected and evaluated for mucociliary relative transport velocity (RTV), displacement in a simulated cough machine (SCM) and contact angle measurement (CAM). For the proposed comparisons, a linear regression model was used with mixed effects with a significance level of 5%.
RESULTS: The Flutter(®)VRP1 treatment resulted in greater displacement in SCM and lower CAM when comparing results from the first (9.6 ± 3.4 cm and 29.4 ± 5.7°, respectively) and fourth weeks of treatment (12.44 ± 10.5 cm and 23.28 ± 6.2°, respectively; p < 0.05). There was no significant difference in the RTV between the treatment weeks for either the Flutter(®)VRP1 or PEP.
CONCLUSION: The use of the Flutter(®)VRP1 for four weeks is capable of altering the respiratory secretion transport properties, and this alteration is related to the high frequency oscillation component.
OBJECTIVE: To separately evaluate the effect of the Flutter(®)VRP1 components (high frequency oscillation and PEP) on mucus transportability in patients with bronchiectasis.
METHODS: Eighteen patients with bronchiectasis received sessions with the Flutter(®)VRP1 or PEP for 30 min daily in a randomized, crossover study. The treatment duration was four weeks with one of the therapies, one week of a "wash-out" period and followed by four more weeks with the other treatment. Weekly secretion samples were collected and evaluated for mucociliary relative transport velocity (RTV), displacement in a simulated cough machine (SCM) and contact angle measurement (CAM). For the proposed comparisons, a linear regression model was used with mixed effects with a significance level of 5%.
RESULTS: The Flutter(®)VRP1 treatment resulted in greater displacement in SCM and lower CAM when comparing results from the first (9.6 ± 3.4 cm and 29.4 ± 5.7°, respectively) and fourth weeks of treatment (12.44 ± 10.5 cm and 23.28 ± 6.2°, respectively; p < 0.05). There was no significant difference in the RTV between the treatment weeks for either the Flutter(®)VRP1 or PEP.
CONCLUSION: The use of the Flutter(®)VRP1 for four weeks is capable of altering the respiratory secretion transport properties, and this alteration is related to the high frequency oscillation component.